Even though in general the data indicate that it would be beneficial to block the NLRP3 inflammasome, the CANTOS trial may have unmasked potential adverse effects as reflected by the worsening of kidney function among subjects with chronic kidney disease in particular in established disease [7]. The gene discussed is NLRP3; the disease is chronic kidney disease.